Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222652 | 0.82 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL10892061 | 0.80 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL28758375 | 0.77 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3145832 | 0.77 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL9593834 | 0.77 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL4196065 | 0.76 | HDAC4 (0.35) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL11175541 | 0.75 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL11175544 | 0.75 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL11175539 | 0.75 | ALDH1A1 (0.33) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 | |
| SCHEMBL15975034 | 0.74 | HDAC4 (0.37) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803837-B2 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803837-B2 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803837-B2 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1701947-B1 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1701947-B1 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARM INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1701947-A2 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005051937-A2 | 4-OXO-4,5-DIHYDRO-FURAN-2-CARBOXYLIC AND ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161701-A1 | 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ABAT, G6PD, GLS2 | HDAC4 775/4885HDAC2 2358/4885HDAC8 1701/4885 |
| US-20070093545-A1 | 4-Oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof | ABAT, G6PD, GLS2 | HDAC4 775/4885HDAC2 2358/4885HDAC8 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.